Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Nussenzweig: Discovery & Characterization of bNAbs |
| Strategy: | Prophylactic neutralizing Ab |
| Study Type: | Phase II |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2015-03-06 |
| Study Made Public: | 2016-12-30 |
Title
A phase 2, open label study of the safety, antiretroviral activity and pharmacokinetics of 3BNC117 during a short analytical treatment interruption in HIV-infected subjects
Description
CAVD 482 is a Phase 2, open label study of the safety, antiretroviral activity and pharmacokinetics of 3BNC117 during a short analytical treatment interruption in HIV-infected subjects..
Sign in to see full information about this study and to download study data.
Products
3BNC117Integrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.